Literature DB >> 1374807

Enhancement of the antibody response to flavivirus B-cell epitopes by using homologous or heterologous T-cell epitopes.

J T Roehrig1, A J Johnson, A R Hunt, B J Beaty, J H Mathews.   

Abstract

We have been investigating the T-helper (Th)-cell response to the flavivirus envelope (E) glycoprotein. In our studies with Murray Valley encephalitis (MVE) virus, we previously identified synthetic peptides capable of priming Th lymphocytes for an in vitro antivirus proliferative response (J. H. Mathews, J. E. Allan, J. T. Roehrig, J. R. Brubaker, and A. R. Hunt, J. Virol. 65:5141-5148, 1991). We have now characterized in vivo Th-cell priming activity of one of these peptides (MVE 17, amino acids 356 to 376) and an analogous peptide derived from the E-glycoprotein sequence of the dengue (DEN) 2, Jamaica strain (DEN 17, amino acids 352 to 368). This DEN peptide also primed the Th-cell compartment in BALB/c mice, as measured by in vitro proliferation and interleukin production. The failure of some MVE and DEN virus synthetic peptides to elicit an antibody response in BALB/c mice could be overcome if a Th-cell epitope-containing peptide was included in the immunization mixture. A more detailed analysis of the structural interactions between Th-cell and B-cell epitope donor peptides revealed that the peptides must be linked to observe the enhanced antibody response. Blockage or deletion of the free cysteine residue on either peptide abrogated the antibody response. The most efficient T-B-cell epitope interaction occurred when the peptides were colinearly synthesized. These Th-cell-stimulating peptides were also functional with the heterologous B-cell epitope-containing peptides. The Th-cell epitope on DEN 17 was more potent than the Th-cell epitope on MVE 17.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374807      PMCID: PMC241118     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Prediction of immunodominant helper T cell antigenic sites from the primary sequence.

Authors:  H Margalit; J L Spouge; J L Cornette; K B Cease; C Delisi; J A Berzofsky
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

2.  The immune response of BALB/c mice to influenza hemagglutinin: commonality of the B cell and T cell repertoires and their relevance to antigenic drift.

Authors:  B C Barnett; C M Graham; D S Burt; J J Skehel; D B Thomas
Journal:  Eur J Immunol       Date:  1989-03       Impact factor: 5.532

3.  Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants.

Authors:  M J Francis; G Z Hastings; A D Syred; B McGinn; F Brown; D J Rowlands
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

4.  Engineering of immunogenic peptides by co-linear synthesis of determinants recognized by B and T cells.

Authors:  F Borras-Cuesta; A Petit-Camurdan; Y Fedon
Journal:  Eur J Immunol       Date:  1987-08       Impact factor: 5.532

5.  Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction.

Authors:  V K Sarin; S B Kent; J P Tam; R B Merrifield
Journal:  Anal Biochem       Date:  1981-10       Impact factor: 3.365

6.  Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans.

Authors:  C D Partidos; M W Steward
Journal:  J Gen Virol       Date:  1990-09       Impact factor: 3.891

7.  Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein.

Authors:  B J Johnson; J R Brubaker; J T Roehrig; D W Trent
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

8.  Immune responses in mice following immunization with chimeric synthetic peptides representing B and T cell epitopes of measles virus proteins.

Authors:  C D Partidos; C M Stanley; M W Steward
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

9.  Neutralizing antibodies to all seven serotypes of foot-and-mouth disease virus elicited by synthetic peptides.

Authors:  M J Francis; G Z Hastings; B E Clarke; A L Brown; C R Beddell; D J Rowlands; F Brown
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

10.  Overlapping T cell antigenic sites on a synthetic peptide fragment from herpes simplex virus glycoprotein D, the degenerate MHC restriction elicited, and functional evidence for antigen-Ia interaction.

Authors:  E Heber-Katz; S Valentine; B Dietzschold; C Burns-Purzycki
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  8 in total

1.  Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design.

Authors:  Daniela Weiskopf; Lauren E Yauch; Michael A Angelo; Daisy V John; Jason A Greenbaum; John Sidney; Ravi V Kolla; Aruna D De Silva; Aravinda M de Silva; Howard Grey; Bjoern Peters; Sujan Shresta; Alessandro Sette
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

2.  Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus.

Authors:  A L Rothman; I Kurane; F A Ennis
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

3.  An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain.

Authors:  J S Wolinsky; E Sukholutsky; W T Moore; A Lovett; M McCarthy; B Adame
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

Review 4.  Dengue and dengue hemorrhagic fever.

Authors:  D J Gubler
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

5.  Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies.

Authors:  I M Antón; S González; M J Bullido; M Corsín; C Risco; J P Langeveld; L Enjuanes
Journal:  Virus Res       Date:  1996-12       Impact factor: 3.303

6.  Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3).

Authors:  Andréa N M Rangel da Silva; Eduardo J M Nascimento; Marli Tenório Cordeiro; Laura H V G Gil; Frederico G C Abath; Silvia M L Montenegro; Ernesto T A Marques
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

7.  Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine.

Authors:  Babu Ramanathan; Chit Laa Poh; Kristin Kirk; William John Hannan McBride; John Aaskov; Lara Grollo
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

Review 8.  Pathogenesis of flavivirus encephalitis.

Authors:  Thomas J Chambers; Michael S Diamond
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.